Continuous glucose monitoring reveals bimodal glycemic patterns during and outside Capivasertib administration

ABSTRACT Capivasertib, an AKT inhibitor, interferes with insulin signaling and can induce hyperglycemia. In this case, we monitored blood glucose fluctuations using continuous glucose monitoring (CGM) during capivasertib administration. During the administration period, a post‐dose increase in blood...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yuya Suzuki, Takeshi Yamaguchi, Takayasu Uchida, Kimio Matsumura, Nozomi Harai, Kaoru Nagasawa, Yuko Tanabe, Koichi Suyama, Takashi Kadowaki, Yasumichi Mori
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-04-01
Edice:	Journal of Diabetes Investigation
Témata:	Capivasertib Continuous glucose monitoring Hyperglycemia
On-line přístup:	https://doi.org/10.1111/jdi.70261
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!